SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

Share Price is delayed by 15 minutes
Get Live Data
17.00    0.00 (0.00%)
Bid:
16.00
Ask:
18.00
Spread: 2.00 (12.50%)
Market Cap: £12.86m
FIPP Live PriceLast checked at - London Stock Exchange

Intraday Frontier Ip Share Chart

Board appointments

31 Mar 2014 07:00

RNS Number : 5183D
Frontier IP Group plc
31 March 2014
 



 

AIM: FIPP

 

Frontier IP Group plc

("Frontier IP" or "the Company")

 

Board changes

 

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce two Board appointments, which both take immediate effect. James Fish has been appointed to the Company as Finance Director and Michael Bourne has been appointed to the Company as a Non-Executive Director.

 

James Fish, a chartered accountant, has over 25 years' experience in senior financial positions and a wide range of commercial experience including venture capital funded small/medium-sized enterprises and start-up companies. He was latterly interim Finance Director at The One Place Capital Limited, an online technology start-up. He qualified as a chartered accountant with KPMG and holds a degree in Accounting and Finance from Heriot Watt University, Edinburgh. James's appointment enables Marilyn Cole to step down as Finance Director and Company Secretary. James will also be appointed Company Secretary.

 

Michael Bourne has almost 30 years' experience in investment management and particular expertise in technology, life sciences and clean technology. He is currently Partner of Accretion Capital LLP and a Director of Cygna Negra Limited and Cygna Negra Malta Limited. He is also an Advisory Board Member of V2R, the US technology transfer venture company. Prior to these roles, in 1995, he founded asset management company, Reabourne Technology Investments Limited, where he was also Chief Investment Officer. For nine years until 2009, he was also a member of the techMARK Advisory Committee.

 

Neil Crabb, Chief Executive of Frontier IP, said,

 

"We are delightedto welcome Jim as Finance Director and Mike as a Non-executive Director. Their appointments strengthen our Board as we continue Frontier IP's development.

 

Jim brings over 25 years' experience as a senior finance professional and his involvement with start-up companies as well as venture capital funded SMEs is especially useful. Mike has substantial experience in investment management and his expertise in the clean energy and life sciences sectors also represents an excellent fit with Frontier IP's activities.

 

As well as welcoming Jim and Mike, I would also like to acknowledge Marilyn's significant contribution to Frontier IP during her time as Finance Director of the Company. She leaves with the Board's best wishes and grateful thanks."

 

The following information is required to be disclosed pursuant to paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

James Milne Fish, aged 56, is or has been a director or partner of the following companies during the previous five years:

 

Current Directorships / Partnerships:

Directorships / Partnerships held within the previous five years:

FD Support Limited

 

In addition, as an interim finance director, Mr Fish has undertaken in the previous five years a finance director role with The One Place Capital Limited, McLaren Software Group Limited and Photo Therapeutics Group Limited. Photo Therapeutics Group Limited entered into a Voluntary Members Liquidation in March 2009, after the return of funds to shareholders following a trade sale of the operating subsidiary.

 

Mr Fish is a member of the Institute of Chartered Accountants of Scotland.

 

Mr Fish currently has no beneficial interest in the share capital of the Company.

 

There are no other matters which are required to be announced with regard to the appointment of Mr Fish under paragraph (g) of Schedule 2 of the AIM Rules.

 

Michael Gerald Bourne, aged 55, is or has been a director or partner of the following companies during the previous five years:

 

Current Directorships / Partnerships:

Directorships / Partnerships held within the previous five years:

Accretion Capital LLP

MGB Technology Consulting Ltd

Coombe Wood Lawn Tennis Club Limited

Cygna Negra Limited

Cygna Negra Malta Limited

 

Mr Bourne currently has no beneficial interest in the share capital of the Company.

 

There are no other matters which are required to be announced with regard to the appointment of Mr Bourne under paragraph (g) of Schedule 2 of the AIM Rules.

 

 

Enquiries

 

Frontier IP Group Plc

0131 220 9491

Neil Crabb, Chief Executive

Company website: www.frontierip.co.uk

 

Cantor Fitzgerald Europe

(Nominated Adviser and Joint Broker)

020 7894 7000

Mark Percy / Catherine Leftley, Corporate Finance

David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited (Joint Broker)

020 7469 0935

Jon Levinson / Lucy Williams

KTZ Communications

020 3178 6378

Katie Tzouliadis / Deborah Walter

 

 

Notes to Editor:

 

Frontier IPspecialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes. www.frontierip.co.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADVLFLZXFEBBK
Date   Source Headline
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project
30th Nov 20225:00 pmRNSTotal Voting Rights
25th Nov 20222:23 pmRNSDirector/PDMR Shareholding
23rd Nov 20225:17 pmRNSDirector share transfers
18th Nov 20223:53 pmRNSExercise of Options & PDMR Shareholdings
11th Nov 20223:07 pmRNSDirector/PDMR Dealing
11th Nov 20227:00 amRNSPosting of Annual Report and Notice of AGM
8th Nov 20227:00 amRNSPulsiv announces £1.5m fundraise
1st Nov 20221:46 pmEQSFrontier IP Group 'rigged for a storm' but confident of more progress
27th Oct 20227:00 amRNSFinal Results
19th Oct 20224:22 pmRNSHolding(s) in Company
19th Oct 20223:29 pmRNSHolding(s) in Company
14th Oct 20227:00 amRNSElute Intelligence appoints Steve Cable as CEO
27th Sep 20227:00 amRNSPulsiv unveils power electronics technology
18th Aug 20223:20 pmRNSSale of shares in Exscientia
5th Aug 20227:00 amRNSCamGraPhIC announces £1.26 million fundraising
26th Jul 20224:26 pmRNSHolding(s) in Company
26th Jul 20224:07 pmRNSHolding(s) in Company
24th May 20227:00 amRNSCambridge Raman Imaging raises £1.1 million
19th May 20227:00 amRNSPublication of newsletter
12th Apr 20225:18 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSUnaudited Half Year Results
14th Feb 20227:00 amRNSSale of shares in Exscientia
11th Feb 20225:04 pmRNSHolding(s) in Company
11th Feb 20222:05 pmRNSHolding(s) in Company
10th Feb 20227:00 amRNSCambridge Raman Imaging wins European Union grant
25th Jan 20227:00 amRNSSale of shares in Exscientia
17th Jan 20225:56 pmRNSHolding(s) in Company
12th Jan 20227:00 amRNSTrading update
11th Jan 20227:00 amRNSCelerum launch first commercial product

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.